|
C4ORF43 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.53149995094782E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.92510000057911E-08 |
| Normal-vs-Stage2 |
1.66759999999933E-05 |
| Normal-vs-Stage3 |
1.88199999995309E-06 |
| Normal-vs-Stage4 |
6.28410000036439E-07 |
| Stage1-vs-Stage2 |
2.023400E-01 |
| Stage1-vs-Stage3 |
8.365800E-01 |
| Stage1-vs-Stage4 |
3.475600E-01 |
| Stage2-vs-Stage3 |
3.059400E-01 |
| Stage2-vs-Stage4 |
7.406400E-01 |
| Stage3-vs-Stage4 |
4.631800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.04379999988203E-08 |
| Normal-vs-AfricanAmerican |
3.96550000000273E-05 |
| Normal-vs-Asian |
2.18799999999186E-05 |
| Caucasian-vs-AfricanAmerican |
5.408200E-01 |
| Caucasian-vs-Asian |
5.654800E-01 |
| AfricanAmerican-vs-Asian |
8.501800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.28269966765049E-10 |
| Normal-vs-Female |
3.73590000046775E-08 |
| Male-vs-Female |
3.211700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.6064999999752E-06 |
| Normal-vs-Age(41-60Yrs) |
1.17950005318335E-09 |
| Normal-vs-Age(61-80Yrs) |
6.06329999541799E-08 |
| Normal-vs-Age(81-100Yrs) |
1.842810E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.573020E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.625590E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.956600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.949600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.274600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.083200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.404600E-01 |
| Classical-VS-Follicular |
2.84560000007872E-07 |
| Classical-VS-Other |
2.185800E-01 |
| Classical-VS-Normal |
3.78450000000363E-05 |
| Tall-VS-Follicular |
3.013800E-04 |
| Tall-VS-Other |
1.394040E-01 |
| Tall-VS-Normal |
1.845980E-01 |
| Follicular-VS-Other |
6.768400E-01 |
| Follicular-VS-Normal |
9.59909929321157E-12 |
| Other-VS-Normal |
8.783700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.70390043688451E-10 |
| Normal-vs-N1 |
4.62710000004307E-06 |
| N0-vs-N1 |
9.774000E-01 |
|
|
